Image: © freshidea/Stock.adobe.com
Suspected cases have been recorded around the world, from Argentina and the US to the UK, Portugal and Thailand. Texas State University’s Dr Rodney E Rohde gives an insight into this latest public health emergency.
A version of this article was originally published by The Conversation (CC BY-ND 4.0)
On 14 August 2024, the World Health Organization declared mpox a public health emergency of international concern. There have been more than 15,600 cases and more than 530 deaths reported in the Democratic Republic of the Congo (DRC) and neighbouring countries in Africa. The disease had previously caused a global outbreak from 2022 to 2023.
Mpox – previously called monkeypox – isn’t a new disease. The first confirmed human case was in 1970, when the virus was isolated from a child suspected of having smallpox in the DRC. Though usually mild, mpox can still potentially cause severe illness. Health officials are concerned that more cases will arise with increased travel.
I’m a researcher who has worked in public health and medical laboratories for more than three decades, especially in the realm of diseases with animal origins. What exactly is happening in the current outbreak, and what does history tell us about mpox?
A cousin of smallpox
Mpox is caused by the monkeypox virus, which belongs to a subset of the Poxviridae family of viruses called Orthopoxvirus. This subset includes the smallpox, vaccinia and cowpox viruses. While an animal reservoir for monkeypox virus is unknown, African rodents are suspected to play a part in transmission. The monkeypox virus has only been isolated twice from an animal in nature. Diagnostic testing for mpox is currently only available at Laboratory Response Network labs around the world.
The name “monkeypox” comes from the first documented cases of the illness in animals in 1958, when two outbreaks occurred in monkeys kept for research. However, the virus did not jump from monkeys to humans, nor are monkeys major carriers of the disease.
Epidemiology
Since the first reported human case, mpox has been found in several other central and west African countries, with the majority of infections in the DRC. Cases outside of Africa have been linked to international travel or imported animals, including in the US and elsewhere.
The first reported cases of mpox in the US was in 2003, from an outbreak in Texas linked to a shipment of animals from Ghana. There were also travel-associated cases in July and November 2021 in Maryland. The outbreak of mpox that began in May 2022 is ongoing.
Because mpox is closely related to smallpox, the smallpox vaccine can provide protection against infection from both viruses. Since smallpox was officially eradicated, however, routine smallpox vaccinations for the US general population were stopped in 1972. Because of this, mpox has been appearing increasingly in unvaccinated people.
Transmission
The virus can be transmitted through contact with an infected person or animal or contaminated surfaces. Typically, the virus enters the body through broken skin, inhalation or the mucous membranes in the eyes, nose or mouth. Researchers believe that human-to-human transmission is mostly through inhalation of large respiratory droplets rather than direct contact with bodily fluids or indirect contact through clothes.
Health officials are worried that the virus may currently be spreading undetected through community transmission, possibly through a new mechanism or route. Where and how infections are occurring are still under investigation.
Signs and symptoms
After the virus enters the body, it starts to replicate and spread through the body via the bloodstream. Symptoms usually don’t appear until one to two weeks after infection.
Mpox produces smallpox-like skin lesions, but symptoms are usually milder than those of smallpox. Flu-like symptoms are common initially, ranging from fever and headache to shortness of breath. One to 10 days later, a rash can appear on the extremities, head or torso that eventually turns into blisters filled with pus. Overall, symptoms usually last two to four weeks, while skin lesions usually scab over in 14 to 21 days.
While mpox is rare and usually nonfatal, one version of the disease kills around 10pc of infected people. The form of the virus currently circulating is thought to be milder, with a fatality rate of less than 1pc.
Vaccines and treatments
Treatment for mpox is primarily focused on relieving symptoms. According to the Centers for Disease Control and Prevention, no treatments are available to cure mpox infection.
Evidence suggests that the smallpox vaccine can help prevent mpox infections and decrease the severity of the symptoms. One vaccine known as Imvamune or Imvanex is licensed in the US to prevent mpox and smallpox.
Vaccination after exposure to the virus may also help decrease chances of severe illness. The CDC currently recommends smallpox vaccination only in people who have been or are likely to be exposed to mpox. Immunocompromised people are at high risk.
Dr Rodney E Rohde specialises in virology, microbiology and molecular biology at Texas State University. His research interests include healthcare associated infections (HAIs), antimicrobial resistance and clinical/public health microbiology, especially zoonotic diseases (rabies, hantavirus, and others).
Find out how emerging tech trends are transforming tomorrow with our new podcast, Future Human: The Series. Listen now on Spotify, on Apple or wherever you get your podcasts.
